• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gilead Sciences acquires Calistoga Pharmaceuticals

Gilead Sciences acquires Calistoga Pharmaceuticals

March 1, 2011
CenterWatch Staff

Gilead Sciences made its third major acquisition in the past eight months, buying privately held Calistoga Pharmaceuticals of Seattle for $375 million cash and $225 million in potential milestones.

Foster City, Calif.-based Gilead, which ended 2010 with $5.3 billion in cash, has made a series of acquisitions to diversify its portfolio by getting into oncology and inflammation treatments ahead of patent expirations for its HIV drugs, according to BioWorld Week. In December 2010, it bought privately held Arresto Biosciences for $225 million in cash plus milestones for its lead candidate AB0024 in phase I testing in solid tumors and idiopathic pulmonary fibrosis. Six months earlier Gilead added an early-stage kinase program by acquiring Branford, Conn.-based CGI Pharmaceuticals in a potential $120 million deal, including milestones.

The key to the Calistoga deal is lead candidate CAL-101, which targets phosphoinositide-3 kinase (PI3K) delta isoform and is in phase II studies as a single agent in patients with refractory indolent non-Hodgkin’s lymphoma (iNHL) and in combination with rituximab in treatment-naïve elderly patients with chronic lymphocytic leukemia (CLL).

The deal follows encouraging fourth-quarter and full-year 2010 results for Gilead that met or exceeded expectations. They included full-year product sales of $7.39 billion, up 14% over 2009, full-year total revenues of $7.95 billion, up 13%, and full-year non-GAAP earnings per share of $3.69, up 21%. The company reported product sales for the fourth quarter increased 7% to $1.93 billion from a year ago.

 

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing